
Capital Raising & Corporate Finance
M&A | IS BIG PHARMAS BIOTECH BINGE ILL-ADVISED?
Capital Markets | Merger & Acquisitions: Biotech
The slew of M&A deals in the pharmaceutical industry could leave some firms with a bad hangover. Fitch Ratings warns that the race to find the next blockbuster drug could hurt overall credit rankings for the sector.